IMR Press / FBL / Volume 14 / Issue 7 / DOI: 10.2741/3394

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

Open Access Article
Silencing of TGase 2 sensitizes breast cancer cells to apoptosis by regulation of survival factors
Show Less
1 Molecular Oncology Branch, Division of Basic and Applied Science, Research Institute, National Cancer Center, Goyang, Kyonggi-do, Republic of Korea
Academic Editor:Alexey Belkin
Front. Biosci. (Landmark Ed) 2009, 14(7), 2514–2521; https://doi.org/10.2741/3394
Published: 1 January 2009
(This article belongs to the Special Issue Cellular functions of tissue transglutaminase)
Abstract

The cross-linking enzyme, Transglutaminase 2 (TGase 2), contributes to physiological homeostasis and plays a role in cell death and survival. We previously showed that down-regulation of TGase 2 by cystamine or synthetic peptide R2 promotes apoptosis in drug-resistant cancer cells by restoring the level of I-κBα, leading to inactivation of NF-κB. To better define the action of TGase 2, its expression was blocked by small interfering RNA. This interference rendered, the doxorubicin-resistant breast cancer cells, highly susceptible to doxorubicin-induced apoptosis. This susceptibility, was associated with decreased levels of the cell-survival factors BCl2 and BCLXL whereas the level of BAX remained un-changed. Together, the findings support the view that TGase 2 leads to drug-resistance by up-regulating the level of survival factors via NF-κB activation.

Share
Back to top